SpaceX Just Tested a Secret Cargo Delivery Vehicle That Could Ship Goods Anywhere on Earth From Space. Here's What Investors Should Know.

On Tuesday, June 23, a SpaceX Falcon 9 lifted off from Cape Canaveral carrying a vehicle most people had never heard of. The payload was called Starfall -- a disc-shaped reentry pod, 10.2 feet wide and 2.5 feet tall, designed to carry up to 1 metric ton of cargo from low-Earth orbit back to Earth's surface.

Space Exploration Technologies (NASDAQ: SPCX) described it publicly as a "microgravity lab" for scientific research and in-space manufacturing. What the Federal Aviation Administration's environmental assessment called it was more specific: a vehicle to "enable point-to-point delivery of critical cargo through space on rapid timelines."

Image source: Getty Images.

Those two descriptions are both accurate, and the gap between them is where the investor story lives.

The vehicle is not capable of de-orbiting itself. It relies on its launch vehicle -- a Falcon 9 today, potentially Starship later -- to guide it back toward the atmosphere, after which it orients its heat shield using compressed nitrogen gas and descends by parachute to a splashdown zone. It's smaller than SpaceX's Crew Dragon, built exclusively for cargo, and recoverable -- SpaceX intends to retrieve the vehicle and its parachutes for reuse.

Two markets to pay attention to

Two markets emerge immediately from that design profile. The first is military logistics. The Pentagon has been working toward a space-based point-to-point cargo delivery capability for years. In 2022, the Air Force Research Laboratory awarded SpaceX a $102 million contract to demonstrate the concept using Starship -- the ability to deliver roughly a C-17 Globemaster's worth of supplies anywhere on the planet in under 90 minutes. Starfall, smaller and deployable on the existing Falcon 9, is a complementary tool for lighter, more targeted deliveries that don't require Starship's enormous footprint or a prepared landing site. The Pentagon has signed similar early-stage agreements with Rocket Lab (NASDAQ: RKLB), Blue Origin, and Anduril for reentry vehicle development. SpaceX is the only company flying a working vehicle today.

The second market is commercial in-space manufacturing, and it's further along than most people realize. Varda Space Industries signed a partnership with United Therapeutics in May 2026 to manufacture drugs in microgravity -- specifically targeting small-molecule crystallization processes that Earth's gravity renders structurally imperfect. Varda CEO Will Bruey put the economics plainly at the 2026 Upfront Summit: A launch capable of processing space-manufactured drugs and returning them to Earth now costs roughly $2.2 million -- a number that makes pharmaceutical microgravity viable at commercial scale for the first time. Starfall, with its 1-metric-ton payload capacity and reusable design, is positioned as the return infrastructure that makes that supply chain possible at volume.

This is where SpaceX's structural advantage over every competitor in this space becomes relevant to investors. Rocket Lab is targeting a 2026 demonstration of reentry capability on its Neutron rocket -- which has not yet flown. Blue Origin is earlier in the development process. Inversion Space received a $71 million contract for its Arc reentry vehicle, which remains in development. SpaceX flew Starfall on Tuesday. That lead time matters in a market where government procurement decisions follow demonstrated capability, not road maps.

The military's REGAL program -- Rocket Experimentation for Global Agile Logistics -- has explicitly framed point-to-point space cargo as a pathway to becoming a program of record, meaning recurring annual defense budget line items rather than one-time research and development (R&D) grants. SpaceX's $102 million AFRL contract was the first significant step in that direction. Starfall's successful demonstration puts the company in a position to substantially expand that relationship.

What this means for SPCX shareholders -- or those interested in investing

Here is where the honest qualification belongs. Starfall's commercial potential is real, but the timelines are long, and the revenue is not yet material on SpaceX's financials. The company's near-term revenue story is Starlink, which generated $4.42 billion in operating income in 2025 and remains the only profitable segment. Even in an optimistic scenario where it wins military contracts and becomes the backbone of orbital pharmaceutical manufacturing, Starfall adds revenue on a multiyear timeline.

For investors looking at SpaceX in a week when the stock has already fallen nearly 30% from its peak due to valuation and float concerns, Starfall is the kind of development that validates the long-term thesis without changing the short-term math.

It is also worth saying plainly: None of this is new. SpaceX has been demonstrating breakthrough capability for years, and investors who needed Tuesday's test to feel confident in the underlying technology were perhaps not paying close enough attention. SpaceX is building real technology that solves real problems.

The question that was true before Tuesday and remains true after it is whether the current price -- which sits 53% above Morningstar's base-case intrinsic value -- gives investors enough room for execution risk on programs that haven't yet generated meaningful revenue.

The technology is not what's in question. The valuation still is.

Micah Zimmerman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.